GangaGen, Inc.


GangaGen, Inc. is a biotechnology company focused on the development of proprietary, bacteriophage-based products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences. The Company's bacteriophage, both natural and engineered, can be applied broadly to kill bacteria pathogenic to humans.

Current Investors/Backers

GangaGen is backed by a group of angel investors and has received an equity investment from ATEL Ventures, Inc.

For more information on GangaGen, Inc. please visit their web site at


ATEL Portfolio News